A share price of Definium Therapeutics Inc [MNMD] is currently trading at $15.02, up 1.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MNMD shares have gain 7.06% over the last week, with a monthly amount glided 19.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Definium Therapeutics Inc [NASDAQ: MNMD] stock has seen the most recent analyst activity on October 13, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $28. On January 28, 2025, Evercore ISI initiated with an Outtperform rating and assigned a price target of $23 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $20 on December 20, 2024. ROTH MKM started tracking with a Buy rating for this stock on July 24, 2024, and assigned it a price target of $36. In a note dated May 29, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $27 on this stock.
Definium Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.70 and $15.29. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Definium Therapeutics Inc [NASDAQ: MNMD] shares were valued at $15.02 at the most recent close of the market. An investor can expect a potential return of 86.42% based on the average MNMD price forecast.
Analyzing the MNMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.71, Equity is -0.86 and Total Capital is -0.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Definium Therapeutics Inc [NASDAQ:MNMD] is 3.30. As well, the Quick Ratio is 3.30, while the Cash Ratio is 0.31.
Transactions by insiders
Recent insider trading involved Karlin Daniel, Chief Medical Officer, that happened on Dec 26 ’25 when 5600.0 shares were sold. Chief Executive Officer, Barrow Robert completed a deal on Dec 26 ’25 to sell 25791.0 shares. Meanwhile, Chief Legal Officer Sullivan Mark sold 11276.0 shares on Dec 26 ’25.
